Novartis’ Diovan Gets Pediatric Hypertension Nod
This article was originally published in The Pink Sheet Daily
Novartis’ top seller will compete with Merck’s Cozaar in the growing pediatric high blood pressure market.
You may also be interested in...
Launch timeframe for the combination of firm’s Diovan and Pfizer’s Norvasc is a few months earlier than previously expected due to recent invalidation of Norvasc patent.
Agency also removes restriction in labeling limiting heart failure indication to patients intolerant of ACE inhibitors.
Arena's Phase IIb CAPTIVATE trial assessing investigational olorinab in IBS missed its primary endpoint.